Mika Okazawa-Sakai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mika Okazawa-Sakai has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Kazuhiro Takehara
Department of Gynecology, NHO Shikoku Cancer Center, Matsuyama, Japan
4 shared publications Etsuko Fujimoto
Department of Gynecologic Oncology, National Hospital Organization (NHO) Shikoku Cancer Center, Matsuyama, Japan
3 shared publicationsKazuhiro Takehara
Department of Gynecologic Oncology, National Hospital Organization (NHO) Shikoku Cancer Center, Matsuyama, Japan
3 shared publicationsShinichi Okame
Department of Gynecologic Oncology, National Hospital Organization (NHO) Shikoku Cancer Center, Matsuyama, Japan
3 shared publicationsTakanori Yokoyama
Department of Gynecologic Oncology, National Hospital Organization (NHO) Shikoku Cancer Center, Matsuyama, Japan
3 shared publications- Daisuke Aoki
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer
Okazawa-Sakai M, et al. J Gynecol Oncol. 2027 ;38:e11. https://doi.org/10.3802/jgo.2027.38.e11
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccesscfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer
Okazawa-Sakai M, et al. J Gynecol Oncol. 2027 ;38:e11. https://doi.org/10.3802/jgo.2027.38.e11
- Open Access
- 11 November 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (2) , 180-186
Current management of hereditary cancer syndromes in ovarian and endometrial cancer: a Japanese study
Background: To evaluate the current state of hereditary cancer syndrome management in patients with ovarian and endometrial cancer and to identify the barriers to uptake of genetic testing. Methods: We conducted a cross-sectional multicenter study at five regional cancer centers in Japan, including 229 patients with ovarian cancer and 454 with endometrial cancer treated between January 2021 and December 2022. We assessed the proportion of patients who received information about hereditary cancer syndromes from gynecologists, underwent genetic counseling with genetic experts, and completed genetic testing; in addition, we explored the barriers to testing uptake. Results: Among patients with ovarian cancer, 152 (66.4%) received information about hereditary cancer syndromes from their gynecologists, with 61 (26.6%) subsequently receiving genetic counseling and 58 (25.3%) undergoing genetic testing. By contrast, patients with endometrial cancer demonstrated markedly lower rates: only 76 (16.7%) received initial information, 22 (5.3%) accessed genetic counseling, and 13 (2.9%) completed genetic testing. Among patients who received information about hereditary cancer syndromes from their gynecologists, 38% with ovarian cancer and 14% with endometrial cancer underwent genetic testing. Among patients identified as high-risk for hereditary cancer syndromes through tumor profiling, 27.6% (8/29) with ovarian cancer and 70.6% (12/17) with endometrial cancer did not undergo genetic testing. Patient disinterest was the primary barrier to genetic testing among high-risk individuals. Conclusions: The barriers to uptake of genetic testing arise primarily from inadequate provider communication and patient disinterest in hereditary cancer syndromes.
- 11 November 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (2) , 180-186
Open AccessCurrent management of hereditary cancer syndromes in ovarian and endometrial cancer: a Japanese study
Background: To evaluate the current state of hereditary cancer syndrome management in patients with ovarian and endometrial cancer and to identify the barriers to uptake of genetic testing. Methods: We conducted a cross-sectional multicenter study at five regional cancer centers in Japan, including 229 patients with ovarian cancer and 454 with endometrial cancer treated between January 2021 and December 2022. We assessed the proportion of patients who received information about hereditary cancer syndromes from gynecologists, underwent genetic counseling with genetic experts, and completed genetic testing; in addition, we explored the barriers to testing uptake. Results: Among patients with ovarian cancer, 152 (66.4%) received information about hereditary cancer syndromes from their gynecologists, with 61 (26.6%) subsequently receiving genetic counseling and 58 (25.3%) undergoing genetic testing. By contrast, patients with endometrial cancer demonstrated markedly lower rates: only 76 (16.7%) received initial information, 22 (5.3%) accessed genetic counseling, and 13 (2.9%) completed genetic testing. Among patients who received information about hereditary cancer syndromes from their gynecologists, 38% with ovarian cancer and 14% with endometrial cancer underwent genetic testing. Among patients identified as high-risk for hereditary cancer syndromes through tumor profiling, 27.6% (8/29) with ovarian cancer and 70.6% (12/17) with endometrial cancer did not undergo genetic testing. Patient disinterest was the primary barrier to genetic testing among high-risk individuals. Conclusions: The barriers to uptake of genetic testing arise primarily from inadequate provider communication and patient disinterest in hereditary cancer syndromes.
- Open Access
- 18 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Prognostic significance of right subdiaphragmatic washing cytology in patients with endometrial cancer
Cancer cells in the right subdiaphragmatic lavage may reflect peritoneal dissemination, but its prognostic significance is unknown. This study investigated recurrence-free survival (RFS), overall survival (OS), and recurrence patterns in patients with curatively resected endometrial cancer by cytology collection site. Peritoneal cytology was collected at the beginning of surgery by washing the pelvic and right subdiaphragmatic cavity separately. The analysis included 465 patients with the median follow-up duration of 121 months. Of these, 62 (13%) patients had positive pelvic cytology and 22 (5%) patients had positive right subdiaphragmatic cytology. Patients positive for right subdiaphragmatic cytology were all positive for pelvic cytology, showing the worst RFS and OS among the study population. Multivariate analyses showed positive right subdiaphragmatic cytology, not pelvic cytology, significantly correlated with shorter RFS and OS when adjusted for clinicopathological factors. Patients with both pelvic and right subdiaphragmatic positive cytology had significantly higher peritoneal recurrence rates than those negative at both sites. However, patients with only positive pelvic cytology showed no significant difference in the recurrence rate. Our results suggest that the prognostic significance of peritoneal cytology may differ depending on the collection site in endometrial cancer and provide new insights to select patients for adjuvant therapy.
- 18 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessPrognostic significance of right subdiaphragmatic washing cytology in patients with endometrial cancer
Cancer cells in the right subdiaphragmatic lavage may reflect peritoneal dissemination, but its prognostic significance is unknown. This study investigated recurrence-free survival (RFS), overall survival (OS), and recurrence patterns in patients with curatively resected endometrial cancer by cytology collection site. Peritoneal cytology was collected at the beginning of surgery by washing the pelvic and right subdiaphragmatic cavity separately. The analysis included 465 patients with the median follow-up duration of 121 months. Of these, 62 (13%) patients had positive pelvic cytology and 22 (5%) patients had positive right subdiaphragmatic cytology. Patients positive for right subdiaphragmatic cytology were all positive for pelvic cytology, showing the worst RFS and OS among the study population. Multivariate analyses showed positive right subdiaphragmatic cytology, not pelvic cytology, significantly correlated with shorter RFS and OS when adjusted for clinicopathological factors. Patients with both pelvic and right subdiaphragmatic positive cytology had significantly higher peritoneal recurrence rates than those negative at both sites. However, patients with only positive pelvic cytology showed no significant difference in the recurrence rate. Our results suggest that the prognostic significance of peritoneal cytology may differ depending on the collection site in endometrial cancer and provide new insights to select patients for adjuvant therapy.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (3)
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer
Okazawa-Sakai M, et al. J Gynecol Oncol. 2024 Oct;36:e38. https://doi.org/10.3802/jgo.2025.36.e38
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (3)
Open AccessGut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer
Okazawa-Sakai M, et al. J Gynecol Oncol. 2024 Oct;36:e38. https://doi.org/10.3802/jgo.2025.36.e38
- 1 December 2023
- Vol. 77 (6) , 627-634
Abnormal Vaginal Cytology after Total Laparoscopic Hysterectomy in Patients with Cervical Intraepithelial Neoplasia
To explore the incidence of abnormal vaginal cytology after total laparoscopic hysterectomy for the treatment of cervical intraepithelial neoplasia 3, we retrospectively analyzed the medical records of patients treated at NHO Shikoku Cancer Center (Japan) in 2014-2019. The cases of 99 patients who underwent a laparoscopic (n= 36) or open (n= 63) hysterectomy and postoperative follow-up were examined. Abnormal vaginal cytology was detected in 13.9% (5/36) of the laparoscopic-surgery (LS) group and 14.3% (9/63) of the open-surgery (OS) group. A vaginal biopsy was performed at the physicians' discretion; one LS patient and six OS patients were diagnosed with vaginal intraepithelial neoplasia. The cumulative incidence of abnormal vaginal cytology at 3 years post-hysterectomy was 21.4% (LS group) and 20.5% (OS group), a nonsignificant difference. A multivariate analysis showed that age > 50 years was the only independent risk factor for abnormal vaginal cytology among the covariates examined including age; body mass index; histories of vaginal delivery, abdominal surgery, and smoking; and surgical approach (hazard ratio 8.11; 95% confidence interval 1.73-37.98; p= 0.01). These results suggest that the occurrence of abnormal vaginal cytology after a hysterectomy may not be influenced by the laparoscopic procedure but is associated with older age.
- 1 December 2023
- Vol. 77 (6) , 627-634
Abnormal Vaginal Cytology after Total Laparoscopic Hysterectomy in Patients with Cervical Intraepithelial Neoplasia
To explore the incidence of abnormal vaginal cytology after total laparoscopic hysterectomy for the treatment of cervical intraepithelial neoplasia 3, we retrospectively analyzed the medical records of patients treated at NHO Shikoku Cancer Center (Japan) in 2014-2019. The cases of 99 patients who underwent a laparoscopic (n= 36) or open (n= 63) hysterectomy and postoperative follow-up were examined. Abnormal vaginal cytology was detected in 13.9% (5/36) of the laparoscopic-surgery (LS) group and 14.3% (9/63) of the open-surgery (OS) group. A vaginal biopsy was performed at the physicians' discretion; one LS patient and six OS patients were diagnosed with vaginal intraepithelial neoplasia. The cumulative incidence of abnormal vaginal cytology at 3 years post-hysterectomy was 21.4% (LS group) and 20.5% (OS group), a nonsignificant difference. A multivariate analysis showed that age > 50 years was the only independent risk factor for abnormal vaginal cytology among the covariates examined including age; body mass index; histories of vaginal delivery, abdominal surgery, and smoking; and surgical approach (hazard ratio 8.11; 95% confidence interval 1.73-37.98; p= 0.01). These results suggest that the occurrence of abnormal vaginal cytology after a hysterectomy may not be influenced by the laparoscopic procedure but is associated with older age.
- 1 November 2023
- Published by Springer Nature
- p. 129-141
Handling Germline Findings in Ovarian Cancer Cases
- 1 November 2023
- Published by Springer Nature
- p. 129-141
Handling Germline Findings in Ovarian Cancer Cases
- Open Access
- 25 July 2022
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33 (5) , e67
Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma
Tanaka T, et al. J Gynecol Oncol. 2022 Jul;33(5):e67. https://doi.org/10.3802/jgo.2022.33.e67
- 25 July 2022
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33 (5) , e67
Open AccessFrequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma
Tanaka T, et al. J Gynecol Oncol. 2022 Jul;33(5):e67. https://doi.org/10.3802/jgo.2022.33.e67
- 14 February 2018
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 23 (4) , 715-725
Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study
Taxane/platinum (TP)-based combination chemotherapy is standard for the treatment of metastatic or recurrent cervical cancer. The aim of this study was to investigate the efficacy of postoperative TP therapy in early stage cervical cancer.
- 14 February 2018
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 23 (4) , 715-725
Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study
Taxane/platinum (TP)-based combination chemotherapy is standard for the treatment of metastatic or recurrent cervical cancer. The aim of this study was to investigate the efficacy of postoperative TP therapy in early stage cervical cancer.
- Open Access
- 1 January 2017
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 28 (1) , e15
Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients
Mabuchi S, et al. J Gynecol Oncol. 2016 Nov;28(1):e15. https://doi.org/10.3802/jgo.2017.28.e15
- 1 January 2017
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 28 (1) , e15
Open AccessChemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients
Mabuchi S, et al. J Gynecol Oncol. 2016 Nov;28(1):e15. https://doi.org/10.3802/jgo.2017.28.e15